0000000000190724

AUTHOR

Delia De Lisi

showing 4 related works from this author

Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?

2015

Purpose: Aim of this study was to investigate for the presence of existing prognostic factors in patients with bone metastases (BMs) from RCC since bone represents an unfavorable site of metastasis for renal cell carcinoma (mRCC). Materials and methods: Data of patients with BMs from RCC were retrospectively collected. Age, sex, ECOG-Performance Status (PS), MSKCC group, tumor histology, presence of concomitant metastases to other sites, time from nephrectomy to bone metastases (TTBM, classified into three groups: <1 year, between 1 and 5 years and >5 years) and time from BMs to skeletal-related event (SRE) were included in the Cox analysis to investigate their prognostic relevance. R…

OncologyAdultMalemedicine.medical_specialtyCancer ResearchPrognosimedicine.medical_treatmentBone NeoplasmsBone NeoplasmPrognostic factorsMetastasisRenal cell carcinomaRetrospective StudieBone metastasis; Prognostic factors; Renal cell carcinoma; Time to distant metastasis; Cancer Research; OncologyInternal medicineBone metastasis Prognostic factors Renal cell carcinoma Time to distant metastasisCarcinomaMedicineHumansLymph nodeCarcinoma Renal CellSurvival analysisAgedRetrospective StudiesBone metastasis; Prognostic factors; Renal cell carcinoma; Time to distant metastasis; Adult; Aged; Aged 80 and over; Bone Neoplasms; Carcinoma Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Cancer Research; OncologyAged 80 and overPrognostic factorTime to distant metastasibusiness.industryResearchTime to distant metastasisBone metastasisKidney NeoplasmBone metastasisMiddle Agedmedicine.diseasePrognosisSurvival AnalysisNephrectomyRenal cell carcinomaKidney Neoplasmsmedicine.anatomical_structureOncologyConcomitantBone metastasiFemaleSurvival AnalysibusinessHumanJournal of Experimental & Clinical Cancer Research
researchProduct

Deregulation of dicer and mir-155 expression in liposarcoma

2015

Liposarcoma (LPS) is the most common soft tissue sarcoma. It has been demonstrated that mir-155 was the most overexpressed miRNA in well-differentiated LPS(WDLPS)/dedifferentiated LPS (DDLPS). The aim of this study is to evaluate the involvement of Dicer, Drosha and mir-155 in development of LPS and their possible role in stratification of different histological subtypes. Dicer, Drosha and mir-155 mRNA levels were analyzed in formalin-fixed paraffin-embedded specimens from patients diagnosed with 62 LPS and compared with samples of adipose tissues of healthy donors. The experimental data were obtained using qRT-PCR comparing Dicer, Drosha and mir-155 expression levels in tumor samples versu…

MaleRibonuclease IIIPathologymedicine.medical_specialtyDEAD-box RNA Helicases -- biosynthesis -- genetics -- metabolismSettore MED/06 - Oncologia MedicaMicroRNAs -- biosynthesis -- geneticsAdipose tissueLiposarcomaRibonuclease III -- biosynthesis -- genetics -- metabolismDroshamiR-155DEAD-box RNA Helicasemir-155DEAD-box RNA HelicasesRetrospective StudiemicroRNAmedicineHumansMicroarray AnalysiDroshaRetrospective StudiesbiologySoft tissue sarcomaAnatomical pathologyMicroRNALiposarcomaSciences bio-médicales et agricolesmedicine.diseaseMicroarray AnalysisLiposarcoma -- genetics -- metabolism -- pathologyDicer; Drosha; liposarcoma; mir-155; DEAD-box RNA Helicases; Female; Humans; Liposarcoma; Male; MicroRNAs; Microarray Analysis; Retrospective Studies; Ribonuclease IIIMicroRNAsOncologyliposarcomabiology.proteinlipids (amino acids peptides and proteins)FemaleClinical Research PaperDicerDicer; Drosha; Liposarcoma; Mir-155; DEAD-box RNA Helicases; Female; Humans; Liposarcoma; Male; MicroRNAs; Microarray Analysis; Retrospective Studies; Ribonuclease III; OncologyHumanDicer
researchProduct

Lack of Correlation between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: A Retrospective Study

2015

AbstractElevation in liver transaminases is common in patients treated with the marine antitumor agent trabectedin. However, the impact of trabectedin-related transaminase elevations on treatment outcomes is unclear. This retrospective study investigated the correlation between liver tests abnormalities and treatment outcomes in patients with unresectable advanced or metastatic soft tissue sarcomas (STS) treated with trabectedin 1.5 mg/m2 once every 3 weeks at three reference centers in Italy. The effect of grade 3/4 elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) during the first two cycles and at any time during trabectedin treatment on progression-free su…

Malemedicine.medical_treatmentSoft Tissue NeoplasmsDioxoleKaplan-Meier EstimateGastroenterologyLiver Function TestsRetrospective StudieTetrahydroisoquinolinesTetrahydroisoquinolineTrabectedinMultidisciplinarybiologymedicine.diagnostic_testLiver Function TestSoft tissue sarcomaAlanine TransaminaseSarcomaMiddle AgedLiverFemaleSarcomamedicine.drugHumanAdultmedicine.medical_specialtyDioxolesdigestive systemArticleDisease-Free SurvivalDrug Administration ScheduleTransaminaseInternal medicinemedicineHumansAspartate AminotransferasesSoft Tissue NeoplasmAntineoplastic Agents AlkylatingRetrospective StudiesAgedChemotherapybusiness.industryRetrospective cohort studyAspartate Aminotransferasemedicine.diseasedigestive system diseasesSurgeryAlanine transaminasebiology.proteinbusinessLiver function testsAdult; Aged; Alanine Transaminase; Antineoplastic Agents Alkylating; Aspartate Aminotransferases; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Liver; Liver Function Tests; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; MultidisciplinaryTrabectedin
researchProduct

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis

2015

We retrospectively reviewed data from 123 patients (KIT exon 11 mutated) who received sunitinib or dose-escalated imatinib as second line. All patients progressed on imatinib (400 mg/die) and received a second line treatment with imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 off or 37.5 mg/day). Deletion versus other KIT 11 mutation was recorded, correlated with clinical benefits. 64% received imatinib, 36% sunitinib. KIT exon 11 mutation was available in 94 patients. With a median follow-up of 61 months, median time to progression (TTP) in patients receiving sunitinib and imatinib was 10 (95% CI 9.7–10.9) and 5 months (95% CI 3.6–6.7) respectively (P = 0.012). No difference wa…

Male0301 basic medicineIndolesTime FactorsGIST; exon 11; imatinib; second line; sunitinibGastroenterologyExon 11Exon0302 clinical medicineSecond linehemic and lymphatic diseasesSunitinibMedicineAged 80 and overGiSTSunitinibExonsMiddle AgedProto-Oncogene Proteins c-kitOncology030220 oncology & carcinogenesisDisease ProgressionImatinib MesylateFemaleResearch PaperGISTmedicine.drugAdultmedicine.medical_specialtyGastrointestinal Stromal TumorsAntineoplastic AgentsDisease-Free Survival03 medical and health sciencesInternal medicineHumansPyrrolesAgedRetrospective StudiesSecond lineSecond line treatmentDose-Response Relationship Drugbusiness.industryRetrospective cohort studyImatinibSurgery030104 developmental biologyImatinib mesylateMutationImatinibbusinessOncotarget
researchProduct